Equities

Pieris Pharmaceuticals Inc

Pieris Pharmaceuticals Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)16.99
  • Today's Change0.83 / 5.14%
  • Shares traded14.86k
  • 1 Year change-32.36%
  • Beta0.6848
Data delayed at least 15 minutes, as of Sep 19 2024 20:59 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Share price forecast

The one analyst offering a 12 month price target expects Pieris Pharmaceuticals Inc share price to fall to 7.00 in the next year from the last price of 16.16.
High-56.7%7.00
Med-56.7%7.00
Low-56.7%7.00

Earnings history & estimates in USD

Earnings forecasts are not available for Pieris Pharmaceuticals Inc. On Aug 14, 2024, Pieris Pharmaceuticals Inc reported 2nd quarter 2024 losses of -- per share.
Average growth rate-20.00%
Pieris Pharmaceuticals Inc reported annual 2023 losses of -21.60 per share on Mar 29, 2024.
Average growth rate+12.69%
More ▼

Revenue history & estimates in USD

Revenue forecasts are not available for Pieris Pharmaceuticals, Inc..
Average growth rate-48.01%
Pieris Pharmaceuticals, Inc. had revenues for the full year 2023 of 42.81m. This was 65.28% above the prior year's results.
Average growth rate+4.56%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.